Landscape of NcRNAs Involved in Drug Resistance of Breast Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2023 Apr 17

PMID 37067729

Authors

Yujuan Kang

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) leads to the most amounts of deaths among women. Chemo-, endocrine-, and targeted therapies are the mainstay drug treatments for BC in the clinic. However, drug resistance is a major obstacle for BC patients, and it leads to poor prognosis. Accumulating evidences suggested that noncoding RNAs (ncRNAs) are intricately linked to a wide range of pathological processes, including drug resistance. Till date, the correlation between drug resistance and ncRNAs is not completely understood in BC. Herein, we comprehensively summarized a dysregulated ncRNAs landscape that promotes or inhibits drug resistance in chemo-, endocrine-, and targeted BC therapies. Our review will pave way for the effective management of drug resistance by targeting oncogenic ncRNAs, which, in turn will promote drug sensitivity of BC in the future.

Citing Articles

Editorial: Non-coding RNAs in breast cancer, volume II.

Zhang W, Kataoka N, Guan X Front Oncol. 2025; 15:1561190.

PMID: 40008003 PMC: 11851079. DOI: 10.3389/fonc.2025.1561190.

Exploring the molecular landscape of osteosarcoma through PTTG family genes using a detailed multi-level methodology.

Lu Y, Wang D, Chen G, Shan Z, Li D Front Genet. 2024; 15:1431668.

PMID: 39139816 PMC: 11319144. DOI: 10.3389/fgene.2024.1431668.

lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways.

Saleh R, Al-Ouqaili M, Ali E, Alhajlah S, Kareem A, Shakir M Med Oncol. 2024; 41(2):52.

PMID: 38195957 DOI: 10.1007/s12032-023-02263-8.

Non-coding RNAs in breast cancer: with a focus on glucose metabolism reprogramming.

Liang J, Ye C, Chen K, Gao Z, Lu F, Wei K Discov Oncol. 2023; 14(1):72.

PMID: 37204526 PMC: 10199155. DOI: 10.1007/s12672-023-00687-2.

References

He M, Jin Q, Chen C, Liu Y, Ye X, Jiang Y . The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells. Oncogene. 2019; 38(28):5551-5565. DOI: 10.1038/s41388-019-0817-3. View

Santen R, Fan P, Zhang Z, Bao Y, Song R, Yue W . Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids. 2009; 74(7):586-94. DOI: 10.1016/j.steroids.2008.11.020. View

Yoon J, Swiderski P, Kaplan B, Takao M, Yasui A, Shen B . Processing of UV damage in vitro by FEN-1 proteins as part of an alternative DNA excision repair pathway. Biochemistry. 1999; 38(15):4809-17. DOI: 10.1021/bi990105i. View

Sheikh M, Solito E . Annexin A1: Uncovering the Many Talents of an Old Protein. Int J Mol Sci. 2018; 19(4). PMC: 5979524. DOI: 10.3390/ijms19041045. View

Sang Y, Chen B, Song X, Li Y, Liang Y, Han D . circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther. 2019; 27(9):1638-1652. PMC: 6731174. DOI: 10.1016/j.ymthe.2019.05.011. View

Fang Z, Wang Y, Wang Z, Xu M, Ren S, Yang D . Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Res. 2020; 80(20):4399-4413. PMC: 7572695. DOI: 10.1158/0008-5472.CAN-20-1031. View

Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E . SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012; 487(7407):380-4. DOI: 10.1038/nature11207. View

Tan S, Ding K, Chong Q, Zhao J, Liu Y, Shao Y . Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J Biol Chem. 2017; 292(33):13551-13564. PMC: 5566515. DOI: 10.1074/jbc.M117.780973. View

Sun F, Lee L, Zhang Z, Wang X, Yu Q, Duan X . Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™. Eur J Pharm Sci. 2015; 77:290-302. DOI: 10.1016/j.ejps.2015.06.021. View

10.

Li X, Kong X, Huo Q, Guo H, Yan S, Yuan C . Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci. 2011; 102(6):1151-7. DOI: 10.1111/j.1349-7006.2011.01919.x. View

11.

Shelly M, Pinkas-Kramarski R, Guarino B, Waterman H, Wang L, Lyass L . Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem. 1998; 273(17):10496-505. DOI: 10.1074/jbc.273.17.10496. View

12.

Tanic N, Milovanovic Z, Tanic N, Dzodic R, Juranic Z, Susnjar S . The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biol Ther. 2012; 13(12):1165-74. PMC: 3469474. DOI: 10.4161/cbt.21346. View

13.

Derdak Z, Mark N, Beldi G, Robson S, Wands J, Baffy G . The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res. 2008; 68(8):2813-9. PMC: 2386271. DOI: 10.1158/0008-5472.CAN-08-0053. View

14.

Soung Y, Chung H, Yan C, Ju J, Chung J . Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b. Cells. 2019; 8(7). PMC: 6679179. DOI: 10.3390/cells8070692. View

15.

Hangauer M, Vaughn I, McManus M . Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013; 9(6):e1003569. PMC: 3688513. DOI: 10.1371/journal.pgen.1003569. View

16.

Rampurwala M, Rocque G, Burkard M . Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl). 2014; 8:125-33. PMC: 4197909. DOI: 10.4137/BCBCR.S9454. View

17.

Xiu D, Liu G, Yu S, Li L, Zhao G, Liu L . Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res. 2019; 38(1):94. PMC: 6385430. DOI: 10.1186/s13046-019-1100-8. View

18.

Nahta R, ORegan R . Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer. 2010; 10 Suppl 3:S72-8. DOI: 10.3816/CBC.2010.s.015. View

19.

Kowaltowski A, de Souza-Pinto N, Castilho R, Vercesi A . Mitochondria and reactive oxygen species. Free Radic Biol Med. 2009; 47(4):333-43. DOI: 10.1016/j.freeradbiomed.2009.05.004. View

20.

Wu D, Zhang J, Lu Y, Bo S, Li L, Wang L . miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1. Cancer Gene Ther. 2018; 26(3-4):74-82. DOI: 10.1038/s41417-018-0035-0. View